EN DE
Watch Singbao International Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Singbao International Co Ltd (6130) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Singbao International Co Ltd stock TWD 6.35, price TWD 24.65, that is 74.2% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006130008

SI Singbao International Co Ltd logo Thin data Nov 3, 2026

Singbao International Co Ltd

6130 · TWO
Very expensive, weak quality

Our calculation puts a fair price 74% below what the stock costs today.

Low debt
Revenue last quarter +28% vs. a year ago.
Mixed Growth (revenue 3y +22.0 %/yr in TWD)
Fair value 6.35 TWD · Strongly overvalued
Quality 37/100
Loss-making · -27.6% net margin (TTM)
Negative free cash flow
Trails peers (2/10)
Narrow moat 21/100
Thin data
Watch Singbao International Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

53.64 TWD 17.53 TWD Fair Value 6.35 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range 17.53 TWD – 53.64 TWD · fair‑value band 4.74 TWD – 9.48 TWD · the 24.65 TWD price screens above the 6.35 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow Singbao International Co in your weekly email

Every Wednesday you see whether Singbao International Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shangya Technology Co., Ltd. engages in the generic drugs and solar power generation businesses in Taiwan and Asia.

Show moreShow less

The company wholesales Chinese and Western medicines, medical equipment, and beauty and hair care products; and onrito, lixin fumitation, lufuxing film-coated, amperex film coating, leverb-coated, triton film-coated, special core stabilized, tanlipo film-coated, inhibitory film-coated, yoyo flat mouth dissolved, and binlishu film-coated tablet, as well as pain relief capsules and yue shi tong injection.

It is also involved in the research, development, production, and sale of wireless communication integrated circuits, satellite positioning system integrated circuits, and portable product ICs. The company was formerly known as Singbao International Co. Ltd and changed its name to Shangya Technology Co., Ltd. in July 2023.

Shangya Technology Co., Ltd. was founded in 1994 and is based in Taipei, Taiwan.

Stock analysis

Singbao International Co Ltd (6130) currently trades at 24.65 TWD, while our model-based Fair Value estimate is 6.35 TWD, 74% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 80/100, which puts the data coverage at low.

Scenario range: 4.74 TWD (bear) to 9.48 TWD (bull), the price of 24.65 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2022: revenue and profit before it include the divested business. Growth is measured afresh from 2022.

Singbao International Co Ltd reported revenue of 155M TWD in FY2025 versus 104M TWD in FY2021, a compound +10.5%/yr. Reported net income was −76.3M TWD in FY2025.

Key figures

Market cap 1.1B TWD (≈ $33.3M) Micro · P/S ratio 6.67 · EPS (TTM) −1.02 TWD · Net margin −27.6% · Return on equity −8.5% · Return on assets (EBIT) −3.7% (5-year average) · Operating margin 5.5% · Revenue (TTM) 165M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (medium confidence).

What moves the price

The share trades about 48% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −74%, 6130 screens richer than that median.

Fair Value models

Bear 4.74 TWD Fair Value 6.35 TWD Bull 9.48 TWD
Price 24.65 TWD · Downside -74.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 4.74 TWD 6.35 TWD 9.48 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 4.74 TWD 6.35 TWD 9.48 TWD 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 8
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 88
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 60
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 74
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2022: revenue and profit before it include the divested business. Growth is measured afresh from 2022.
Revenue growth 1 year
−20.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−13.5% (2020) → −47.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6130 screens overvalued: fair value 74% below the price. Compare with Eli Lilly and Company →

Compare Singbao International Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −74.2% · Bottom 25%
Profitability
Return on assets −8.7% · Bottom 25%
Net margin (12 months) −27.6% · Bottom 25%
Operating margin (12 months) 5.5% · Below median
Growth and dividend
Revenue growth (quarter YoY) 28.2% · Top 25%
Balance sheet
Debt / equity 0.16× · Above median

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/B 2.00× · Cheaper than median
P/S (12 months) 6.61× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 20
FUTURE (revenue growth)100 · sector 34
PAST (return on equity)0 · sector 41
HEALTH (low debt)92 · sector 93
DIVIDEND (yield)0 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Bristol-Myers Squibb Company BMY $62.14 $75.91 +22% vs 6130
Gilead Sciences, Inc GILD $166.89 $183.58 +10% vs 6130
Amgen Inc AMGN $460.42 $506.31 +10% vs 6130
Novartis AG NOVN CHF 133.08 CHF 120.24 −10% vs 6130
AbbVie Inc ABBV $291.31 $259.62 −11% vs 6130
Merck & Co MRK $146.73 $129.26 −12% vs 6130
Pfizer Inc PFE $29.39 $24.87 −15% vs 6130
Roche Holding RO CHF 400.00 CHF 326.56 −18% vs 6130
Johnson & Johnson, JNJ $276.22 $168.85 −39% vs 6130
Eli Lilly and Company LLY $1,354 $749.92 −45% vs 6130

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Singbao International Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Singbao International Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6130

Frequently asked questions

Is Singbao International Co Ltd (6130) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 6.35 TWD versus a price of 24.65 TWD, about 74% lower (overvalued).
What is the fair value of 6130?
Our model-based fair value for Singbao International Co Ltd is 6.35 TWD (as of Nov 3, 2026), built from audited fundamentals. The current price: 24.65 TWD.
What is the quality score of 6130?
Singbao International Co Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Singbao International Co Ltd (6130)?
Our model-based price target is the fair value of 6.35 TWD (as of Nov 3, 2026) from 1 valuation models. Cautious scenario 4.74 TWD, optimistic scenario 9.48 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Singbao International Co Ltd stock forecast for 2026?
Our models put fair value at 6.35 TWD, about 74% lower versus a price of 24.65 TWD (overvalued). Cautious scenario 4.74 TWD, optimistic scenario 9.48 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Singbao International Co Ltd (6130)?
Singbao International Co Ltd reported trailing-twelve-month revenue of about 165M TWD (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Singbao International Co Ltd (6130)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Singbao International Co Ltd it is 6.35 TWD per share (as of Nov 3, 2026), against a price of 24.65 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Singbao International Co Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 6130 trades above its calculated fair value: price 24.65 TWD, fair value 6.35 TWD, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6130?
No. The price is what the market pays today (24.65 TWD); the fair value is what the company's own numbers justify (6.35 TWD). For Singbao International Co Ltd the two are 18.30 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Singbao International Co Ltd worth?
The market values Singbao International Co Ltd at about 1.1B TWD (market capitalisation, as of Nov 3, 2026). Per share that is 24.65 TWD; our models calculate a fair value of 6.35 TWD per share.
What do the bullish and bearish scenarios say about 6130?
Our models span a range for Singbao International Co Ltd: cautious scenario 4.74 TWD, base 6.35 TWD, optimistic 9.48 TWD per share (as of Nov 3, 2026, price 24.65 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Singbao International Co Ltd (6130)?
Balance-sheet figures for Singbao International Co Ltd (as of Nov 3, 2026): return on equity −8.5%, debt of 0.16 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 6130 from its 52-week high?
Singbao International Co Ltd trades at 24.65 TWD, about 48% below its 52-week high of 47.25 TWD and 15% above the low of 21.35 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 6.35 TWD is for.
Which stocks are comparable to Singbao International Co Ltd?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Singbao International Co Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 24.65 TWD, calculated fair value 6.35 TWD (−74%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6130 calculated?
We run Singbao International Co Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 6.35 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Singbao International Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Singbao International Co Ltd (6130)?
The closing price on Nov 6, 2026 was 24.65 TWD. Our model-based fair value is 6.35 TWD, about 74% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Singbao International Co Ltd right now?
The price sits above even our optimistic bull case (9.48 TWD). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (4.74 TWD to 9.48 TWD) leaves room in how you read the outcome.

Key figures of Singbao International Co Ltd

How large is the market capitalisation of Singbao International Co Ltd (6130)?
The market capitalisation of Singbao International Co Ltd is 1.1B TWD (≈ $33.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Singbao International Co Ltd (6130)?
The price-to-sales ratio of Singbao International Co Ltd is 6.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Singbao International Co Ltd (6130)?
Earnings per share at Singbao International Co Ltd are −1.02 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Singbao International Co Ltd (6130)?
The net margin of Singbao International Co Ltd is −27.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Singbao International Co Ltd (6130)?
The return on equity (ROE) of Singbao International Co Ltd is −8.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Singbao International Co Ltd (6130)?
On an EBIT basis the return on assets of Singbao International Co Ltd is −3.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Singbao International Co Ltd (6130)?
The operating margin of Singbao International Co Ltd is 5.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Singbao International Co Ltd (6130)?
Revenue at Singbao International Co Ltd is growing +28.2% versus a year earlier (3y avg +22.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Singbao International Co Ltd (6130)?
Earnings per share at Singbao International Co Ltd are growing −89.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Singbao International Co Ltd (6130) generate?
The free cash flow of Singbao International Co Ltd is −120M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Singbao International Co Ltd (6130) hold?
Singbao International Co Ltd holds more cash than debt, 114M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Singbao International Co Ltd in the live analysis

One click puts Singbao International Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.